Skip to main content

THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia

Objective

THALAMOSS is aimed at development of universal sets of markers and techniques for stratification of β-thalassaemia patients into treatment subgroups for (a) onset and frequency of blood transfusions, (b) choice of iron chelation, (c) induction of fetal hemoglobin, (d) prospective efficacy of gene-therapy. At present, no framework exists to guide therapeutic decisions and personalised treatment of β-thalassaemia.
THALAMOSS Workpackages: WP1. Recruitment, patient characterization and development of erythroid precursor cells cultures; WP2. Omics analyses; WP3. Novel therapeutic approaches; WP4. Data analysis; WP5. Dissemination and exploitation; WP6. Regulatory and ethical issues; WP7. Management.
The impact of THALAMOSS is the provision of novel biomarkers for distinct treatment subgroups in β-thalassaemia (500-1000 samples from four European medical centres), identified by combined genomics, proteomics, transcriptomics and tissue culture assays, and establishment of routine techniques for detection of these markers. Translation of these activities into the product portfolio and R&D methodology of participating SMEs will be a major issue. THALAMOSS tools and technologies will (a) facilitate identification of novel diagnostic tests, drugs and treatments specific to patient subgroups and (b) guide conventional and novel therapeutical approaches for β-thalassaemia, including personalised medical treatments.
Key researchers of THALAMOSS are R.Gambari (Ferrara University, Italy), M. Kleanthous (The Cyprus Foundation for Muscular Dystrophy Research, Cyprus), S.Philipsen (Erasmus Universitair Medisch Centrum Rotterdam, The Netherlands), E.Katsantoni (Biomedical Research Foundation, Academy of Athens, Greece), S.Rivella (Cornell University, NY, USA - The Children's Hospital of Philadelphia, Philadelphia, USA), P.Holub (Masaryk University, Czech Republic), P. Moi (Cagliari University, Italy), S. Menzel and SL.Thein (King’s College Hospital, UK), E.Voskaridou (Laiko General Hospital, Greece). Participating SMEs are Biocep (Israel), NovaMechanics Ltd. (Cyprus) and IRBM (Italy). Industrial activities are also provided by Harbour Antibodies (The Netherlands).

Field of science

  • /medical and health sciences/basic medicine/neurology/muscular dystrophy
  • /natural sciences/chemical sciences/inorganic chemistry/inorganic compounds
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins/proteomics
  • /natural sciences/computer and information sciences/data science/data analysis

Call for proposal

FP7-HEALTH-2012-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

UNIVERSITA DEGLI STUDI DI FERRARA
Address
Via Ariosto 35
44121 Ferrara
Italy
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 584 000
Administrative Contact
Roberto Gambari (Prof.)

Participants (13)

THE CYPRUS FOUNDATION FOR MUSCULAR DYSTROPHY RESEARCH
Cyprus
EU contribution
€ 440 000
Address
International Airport Avenue 6
1683 Ayios Dometios
Activity type
Research Organisations
Administrative Contact
Marios Flouros (Mr.)
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 370 000
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Riet Zeijl (Mrs.)
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Greece
EU contribution
€ 370 000
Address
Soranou Efesiou 4
115 27 Athina
Activity type
Research Organisations
Administrative Contact
Dimitris Raptis (Mr.)
CORNELL UNIVERSITY
United States
EU contribution
€ 233 587,33
Address
Pine Tree Road 373
14850 Ithaca Ny
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Michelle Lewis (Ms.)
Masarykova univerzita
Czechia
EU contribution
€ 320 000
Address
Zerotinovo Namesti 9
60177 Brno Stred
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Petr Holub (Dr.)
UNIVERSITA DEGLI STUDI DI CAGLIARI
Italy
EU contribution
€ 320 000
Address
Via Universita 40
09124 Cagliari
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tiziana Cubeddu (Mrs.)
KING'S COLLEGE LONDON
United Kingdom
EU contribution
€ 320 000
Address
Strand
WC2R 2LS London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Paul Labbett (Mr.)
GENIKO LAIKO NOSOKOMEIO ATHINON*GENERAL HOSPITAL OF ATHENS LAIKO
Greece
EU contribution
€ 320 000
Address
Agiou Thoma 17
11527 Athina
Activity type
Research Organisations
Administrative Contact
Ersi Voskaridou (Dr.)
NOVAMECHANICS LIMITED
Cyprus
EU contribution
€ 620 477,53
Address
Prigkipissis Nte Tyras 16 Karantoki Building 5Th Floor Flat/office 13-14
1065 Nicosia
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Antreas Afantitis (Dr.)
BIOCEPS
Israel
EU contribution
€ 97 761
Address
Ziv Medical Center, The Research Department, Harambam Street
1311001 Tzfat
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Eitan Fibach (Prof.)
HARBOUR ANTIBODIES BV
Netherlands
EU contribution
€ 100 000
Address
Stationsplein 45, A4.004
3013 AK Rotterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Riet Van Zeijl (Ms.)
IRBM SCIENCE PARK SPA
Italy
EU contribution
€ 787 761,47
Address
Via Pontina Km 30600
00040 Pomezia Rm
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ilaria Iannaccone (Dr.)
THE CHILDREN'S HOSPITAL OF PHILADELPHIA NON PROFIT ORG
United States
EU contribution
€ 136 412,67
Address
Civic Center Blvd
19104 Philadelphia
Activity type
Other
Administrative Contact
Robert Denight (Mr.)